Bruker (BRKR) AI Stock Analysis

• Market Cap: $7.47B
• Dividend Yield: 0.42%
• Average Volume (3M): 1.93M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: 6.10%
• EPS Growth: -107.47%
• Country: US
• Employees: 11,396
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.45
• Shares Outstanding: 151,941,150
• 10 Day Avg. Volume: 2,067,163
• 30 Day Avg. Volume: 1,930,620
• PEG Ratio: -1.04
• Price to Book (P/B): 4.90
• Price to Sales (P/S): 2.59
• P/FCF Ratio: 64.22
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 1.93
• Enterprise Value/Gross Profit: 4.08
• Enterprise Value/Ebitda: 23.02
• 1Y Price Target: $52.18
• Price Target Upside: 2.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: $54.00 ▲(6.13% Upside)

Bruker's overall stock score reflects significant challenges in financial performance, particularly in revenue growth and cash flow management. While technical indicators show positive momentum, the valuation remains concerning with a negative P/E ratio. The earnings call provided a mixed outlook, with some positive developments but ongoing operational challenges. The strategic board appointment is a positive move but does not heavily influence the current score.

Positive Factors

Strategic Board Appointment

The addition of Jack Phillips, with his extensive diagnostics industry experience, is expected to enhance Bruker's strategic direction and market positioning, potentially driving long-term growth in its diagnostics portfolio.

Cost Savings Initiatives

Bruker's successful cost-saving initiatives are expected to deliver significant margin expansion and double-digit EPS growth in 2026, enhancing financial stability and profitability.

Growth in Diagnostics and Spatial Biology

Strong growth in diagnostics and spatial biology segments indicates robust demand and potential for sustained revenue expansion, strengthening Bruker's market position.

Negative Factors

Declining Revenue Growth

The decline in revenue growth reflects challenges in market demand and competitive pressures, potentially impacting long-term financial performance and market share.

Operational and Margin Challenges

Decreased operating margins indicate operational inefficiencies and cost pressures, which could hinder profitability and financial flexibility over the long term.

Revenue Pushouts to 2026

Delays in revenue recognition due to order pushouts can strain cash flow and create uncertainty in financial projections, affecting investor confidence and strategic planning.

Bruker Business Overview & Revenue Model

Company Description

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

How the Company Makes Money

Bruker generates revenue through the sale of its scientific instruments, software, and services. The principal revenue streams include the sale of new instruments and systems, which are often high-value items, and recurring revenue from service contracts, maintenance, and software licenses. Additionally, Bruker benefits from consumables and accessories linked to its scientific instruments. The company also engages in strategic partnerships and collaborations with academic institutions, research organizations, and industry leaders to enhance its product offerings and expand its market reach, which further contributes to its financial growth.

Bruker Financial Statement Overview

Summary

Bruker's financial performance is challenged by declining revenue growth and cash flow issues. The income statement shows a decline in revenue growth rate and profitability margins, while the balance sheet remains stable with a slightly high debt-to-equity ratio. Cash flow generation is weak, with negative free cash flow and low liquidity ratios.

Income Statement

Bruker's income statement shows a mixed performance. The TTM data indicates a decline in revenue growth rate at -11.3%, which is concerning. However, the company maintains a reasonable gross profit margin of 48% and a net profit margin of 2.31%. The EBIT and EBITDA margins have decreased compared to previous years, indicating potential challenges in operational efficiency.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 1.34, which is slightly high but manageable. The return on equity has decreased to 4.4% in the TTM, suggesting reduced profitability. However, the equity ratio remains healthy, indicating a solid asset base.

Cash Flow

The cash flow statement reveals some weaknesses, particularly in free cash flow, which has turned negative in the TTM. The operating cash flow to net income ratio is low at 0.12, indicating potential liquidity issues. The free cash flow to net income ratio is 0.30, showing limited cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.44B	3.37B	2.96B	2.53B	2.42B	1.99B
Gross Profit	1.63B	1.65B	1.51B	1.31B	1.21B	939.80M
EBITDA	288.60M	438.60M	675.50M	518.70M	497.10M	320.60M
Net Income	-20.90M	113.10M	427.20M	296.60M	277.10M	157.80M
Balance Sheet
Total Assets	6.43B	5.81B	4.25B	3.61B	3.65B	3.05B
Cash, Cash Equivalents and Short-Term Investments	295.00M	183.40M	488.30M	645.50M	1.17B	731.80M
Total Debt	2.05B	2.25B	1.38B	1.27B	1.39B	912.80M
Total Liabilities	3.94B	3.99B	2.84B	2.48B	2.57B	2.07B
Stockholders Equity	2.43B	1.78B	1.38B	1.11B	1.07B	961.20M
Cash Flow
Free Cash Flow	-10.60M	136.00M	243.20M	145.20M	190.40M	235.00M
Operating Cash Flow	94.30M	251.30M	350.10M	274.40M	282.40M	332.20M
Investing Cash Flow	-201.60M	-1.76B	-326.00M	-251.60M	-192.40M	-192.70M
Financing Cash Flow	227.70M	1.23B	-193.40M	-415.30M	318.70M	-161.60M

Bruker Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 50.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 50.88 is above the 20-day moving average (MA) of 49.10, above the 50-day MA of 46.33, and above the 200-day MA of 39.35, indicating a bullish trend. The MACD of 1.71 indicates Positive momentum. The RSI at 50.95 is Neutral, neither overbought nor oversold. The STOCH value of 45.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.

Bruker Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMED	82 Outperform	$12.45B	29.88	10.01%	―	11.75%	364.73%
ITGR	65 Neutral	$2.97B	35.46	5.18%	―	7.81%	-26.32%
BRKR	63 Neutral	$7.47B	-314.40	-0.99%	0.42%	6.10%	-107.47%
LIVN	63 Neutral	$3.32B	-15.17	-17.63%	―	8.97%	-1024.86%
GKOS	58 Neutral	$6.00B	―	-12.19%	―	30.38%	47.64%
BIO	54 Neutral	$8.58B	-13.09	-9.50%	―	-0.88%	10.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bruker Corporate Events

Bruker clarifies regulatory filing status in recent 8-K

In a recent regulatory filing, Bruker clarified that certain information furnished in Item 2.02 and Item 7.01 of its current report on Form 8-K is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and will not automatically be incorporated into other securities law filings. This delineation underscores the company’s intent to limit potential legal exposure and maintain control over how specific disclosures are referenced in future filings, which is relevant for investors and other stakeholders tracking the legal and regulatory status of its reported information.

The most recent analyst rating on (BRKR) stock is a Hold with a $53.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.

Bruker Appoints Jack Phillips to Board of Directors

On December 8, 2025, Bruker Corporation announced the appointment of Jack J. Phillips to its Board of Directors, effective January 1, 2026. Phillips, a seasoned executive with over 30 years in the diagnostics industry, is expected to bring valuable strategic and market development experience to Bruker as it expands its infectious disease diagnostics portfolio. His previous roles include President & CEO of Accelerate Diagnostics and Roche Diagnostics North America, where he contributed significantly to advancements in diagnostics technology. This strategic addition to the board is anticipated to enhance Bruker’s industry positioning and foster business growth.

The most recent analyst rating on (BRKR) stock is a Hold with a $49.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.